share_log

BioVie | 424B5: Prospectus

BioVie | 424B5: Prospectus

BioVie | 424B5：募资说明书
美股SEC公告 ·  09/24 17:32

Moomoo AI 已提取核心信息

BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,360,800 shares of its Class A common stock at a price of $1.53 per share. Additionally, the company is offering pre-funded warrants to purchase up to 600,000 shares of common stock and warrants to purchase up to 1,960,800 shares of common stock. The pre-funded warrants, exercisable at $0.0001 per share, cater to purchasers who would otherwise own more than 4.99% of the issued and outstanding common stock post-offering. The common warrants, exercisable at $1.53 per share, will be immediately exercisable and expire five years from the issuance date. ThinkEquity LLC acts as the exclusive placement agent for the offering. The placement agent will use reasonable best efforts to arrange for the sale of the securities, but is not obligated to sell any specific number or dollar amount. The offering is expected to close on or about September 25, 2024, subject to customary closing conditions.
BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,360,800 shares of its Class A common stock at a price of $1.53 per share. Additionally, the company is offering pre-funded warrants to purchase up to 600,000 shares of common stock and warrants to purchase up to 1,960,800 shares of common stock. The pre-funded warrants, exercisable at $0.0001 per share, cater to purchasers who would otherwise own more than 4.99% of the issued and outstanding common stock post-offering. The common warrants, exercisable at $1.53 per share, will be immediately exercisable and expire five years from the issuance date. ThinkEquity LLC acts as the exclusive placement agent for the offering. The placement agent will use reasonable best efforts to arrange for the sale of the securities, but is not obligated to sell any specific number or dollar amount. The offering is expected to close on or about September 25, 2024, subject to customary closing conditions.
BioVie Inc.是一家临床阶段的公司，专注于开发治疗肝脏疾病和神经疾病的药物疗法，宣布以1.53美元每股的价格发行1,360,800股A类普通股。此外，该公司还发行可卖出预融资认股权，购买多达600,000股普通股的权证以及购买多达1,960,800股普通股的权证。预融资认股权每股行使价为0.0001美元，满足购买者否则将拥有已发行和流通普通股后超过总发售量4.99%的要求。普通认股权每股行使价为1.53美元，将立即行使，并在发行日期起计五年后到期。ThinkEquity LLC担任本次发售的独家承销代理。承销代理将尽力安排出售证券，但无义务出售任何特定数量或金额的证券。本次发行预计将于2024年9月25日或前后结束，视习惯的结束条件而定。
BioVie Inc.是一家临床阶段的公司，专注于开发治疗肝脏疾病和神经疾病的药物疗法，宣布以1.53美元每股的价格发行1,360,800股A类普通股。此外，该公司还发行可卖出预融资认股权，购买多达600,000股普通股的权证以及购买多达1,960,800股普通股的权证。预融资认股权每股行使价为0.0001美元，满足购买者否则将拥有已发行和流通普通股后超过总发售量4.99%的要求。普通认股权每股行使价为1.53美元，将立即行使，并在发行日期起计五年后到期。ThinkEquity LLC担任本次发售的独家承销代理。承销代理将尽力安排出售证券，但无义务出售任何特定数量或金额的证券。本次发行预计将于2024年9月25日或前后结束，视习惯的结束条件而定。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间